查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球動物生物技術市場-2022-2029
市場調查報告書
商品編碼
1129273

全球動物生物技術市場-2022-2029

Global Animal Biotechnology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

基因工程的最新進展預計將推動市場增長。

近年來基因工程的研究和發展擴大了生物技術在畜牧業的研究和應用領域。為食用而飼養的動物，如牛和雞，其肉和奶中含有優質蛋白質、必需氨基酸、礦物質、脂肪、易吸收的維生素、微量碳水化合物和其他生物活性物質。畜牧業利用生物技術促進品種開發，以改善動物福利和健康，提高生育能力，並提高動物衍生產品的營養質量和安全性。人工授精、體外受精、體細胞核移植等多種生物技術提高了動物的生育能力。例如，使用 DNA 標記來闡明動物的遺傳特徵並預測它們的能力在動物生物技術中很有用。標記輔助選擇是一種間接選擇有趣性狀的遺傳決定因素的技術。許多性狀由多個基因座控制，每個基因座稱為數量性狀基因座，並有助於性狀變異。如果在胚胎中發現重要的數量性狀基因座，生產者可以選擇轉移或丟棄胚胎。只有與基因或目標屬性密切相關的遺傳標記才能保證實際的育種成功。

此外，重組 DNA 技術也是一種將稱為 rDNA 的重組 DNA 分子插入宿主生物體以產生對動物有益的獨特基因融合的方法。 DNA疫苗可用於生產動物疫苗，產生多個基因拷貝或將外源基因插入其他物種以賦予新的特徵，例如抗生素抗性，從而產生有效且持久的細胞，可引發性免疫反應。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

動物生物技術產品的高成本、與動物生物技術產品相關的倫理問題、缺乏熟練的專業人員進行診斷測試等是預計在預測期內阻礙市場的一些因素。是一個因素。

行業分析

動物生物技術市場根據各種行業因素（包括搬運工五力、供應鏈、定價分析和監管批准）對市場進行了深入分析。

COVID-19 影響分析

COVID-19 大流行對市場產生了適度的影響。冠狀病毒大流行使生物技術研究的潛在好處和陷阱成為人們關注的焦點。此類研究可用於開發抗擊疾病的醫學療法、更健康的作物和牲畜，並可能用於製造生物武器。世界各地的研究人員都在積極抗擊這一流行病。他們正在使用諸如開發廉價的診斷方法、重新利用現有的抗病毒藥物、發現新藥以及製造可靠和有效的疫苗等技術。

此外，生物技術還可以生產可以有意釋放到環境中的轉基因生物，例如用於蚊子控制。例如，基因組工程技術的發展，如 CRISPR（成簇的規則間隔的短回文重複序列）和 Cas9（CRISPR 相關蛋白 9），使得創建基因驅動成為可能。使用這種方法，所需的遺傳改變可以在幾代人的整個人群中迅速傳播。該技術可以通過使蚊子對引起這些疾病的寄生蟲產生抵抗力或完全消滅攜帶疾病的蚊子種群來治療瘧疾和登革熱等媒介人類疾病。另一方面，受疫情影響，中小型企業對動物醫院的探訪也面臨挑戰。因此，大流行擾亂了供應鏈。因此，COVID-19 大流行正在影響市場。但是，預計情況將在預測期內逐漸改善。

全球動物生物技術市場報告將提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 基因工程的進步有望推動市場增長
    • 限制因素
      • 預計動物生物技術產品的高成本將在預測期內受到阻礙。
    • 市場機會
    • 影響分析

第五章行業分析

  • 波特的五種力量
  • 未滿足的需求
  • 供應鏈
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按動物類型

  • 牲畜
    • 魚
    • 家禽
    • 豬
    • 牛
    • 綿羊/山羊
    • 其他
  • 伴侶
      • 狗
      • 貓科
      • 馬
      • 水生動物
      • 鳥類
      • 其他

第 8 章按產品類型

  • 藥物
  • 疫苗接種
  • 診斷試劑
  • 基因和生殖產品
  • 其他

第 9 章。按應用程序

  • 動物疾病診斷
  • 動物疾病的治療
  • 動物預防醫學
  • 藥物開發
  • 其他

第 10 章，最終用戶

  • 獸醫醫院和診所
  • 實驗室
  • 內部檢查
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 13 章公司簡介

  • 勃林格殷格翰有限公司
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Merck & Co.,Inc.
  • Virbac
  • Elanco
  • Zoetis
  • Biogenesis Bago
  • Idexx Laboratories
  • Heska Corporation
  • Indian Immunologicals Ltd.
  • HESTER BIOSCIENCES LIMITED

第 14 章全球動物生物技術市場 - DataM

簡介目錄
Product Code: DMBT5846

Market Overview

Animal Biotechnology Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Animal biotechnology refers to using engineering, science, and technology to modify and improve living organisms such as animals. Animal biotechnology can also be further explained as part of biotechnology, where molecular biotechnology techniques are used to genetically manipulate or modify the genome of various animals to improve their suitability for various applications such as pharmaceutical, industrial or agricultural applications. In the same case, animal biotechnology uses multiple methods to diagnose the various diseases in animals, allow the treatment of these diseases through multiple therapeutic options and the development of veterinary drugs, and the preventive care of animals through veterinary vaccines. The vaccination process is a highly effective and crucial tool for preventing animal diseases and promoting animal health and welfare, safe food production and public health.

Market Dynamics

Recent advances in genetic engineering are expected to drive market growth.

Recent developments in genetic engineering have widened the area of biotechnology research and application in farm animals. Animals raised for food, such as cattle and poultry, provide high-quality protein, essential amino acids, minerals, fats, easily absorbed vitamins, trace amounts of carbohydrates, and other bioactive substances in their meat and milk. In the livestock industry, biotechnology is being used to accelerate breed development for greater animal welfare and health, increased reproduction, and improved nutritional quality and safety of products obtained from animals. Through a range of biotechnological techniques, such as artificial insemination, in-vitro fertilization, and somatic cell nuclear transfer, animal breeding stock is thus improved. For instance, using DNA markers to describe an animal's genetic make-up and predict its performance is useful in animal biotechnology. Marker-assisted selection is a technique for indirectly selecting a genetic determinant of an interesting feature. Many traits are governed by multiple genetic loci, each of which is referred to as a quantitative trait locus and contributes to the trait's variation. The producer may be given the option of transferring or discarding the embryo if significant quantitative characteristic loci are found in the embryo. Only genetic markers strongly related to the genes or objective attributes can ensure successful breeding in practice.

Additionally, recombinant DNA technology is another method that allows the creation of unique genetic fusions advantageous to animals by inserting a recombined DNA molecule known as rDNA into a host organism. DNA vaccines can elicit potent, long-lasting cellular immune responses because it enables the production of numerous copies of genes and the insertion of foreign genes into other species to impart new traits like antibiotic resistance and the production of animal vaccines. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of animal biotechnology products, ethical concerns related to animal biotechnology products and lack of skilled professionals to perform diagnostic tests are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The animal biotechnology market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The coronavirus pandemic has brought biotechnology research's potential benefits and pitfalls into focus. Although such research can be used to develop medical countermeasures to combat disease and to develop healthier crops and livestock, it can also be used to create biological weapons. Researchers from all across the world are aggressively battling the pandemic. They've utilized several technologies to develop affordable diagnostics, repurpose current antivirals, find novel medicines, and manufacture certain and efficient vaccinations.

Additionally, genetically modified organisms that can be purposefully released into the environment for things like mosquito control can be made via biotechnology. For instance, developments in genome engineering technologies, like clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), have made it possible to create gene drives. This method enables desired genetic alterations to spread quickly throughout a population over several generations. This technique can cure vector-borne human diseases such as malaria and dengue fever by either making mosquitoes resistant to the parasites that cause these diseases or completely wiping out disease-carrying mosquito populations. In contrast, medium- and small-sized enterprises had challenges due to the pandemic's restrictions on veterinary clinic visits. Therefore, the pandemic is interrupting the supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Vaccinations segment is expected to hold the largest market share in animal biotechnology market.

The vaccinations segment accounted for the largest market share in 2021. The segment is benefited from the rising incidence of animal diseases, which naturally spread from animals to humans through consumption of contaminated food and water or direct contact with plagued individuals. Animal illness burden can be decreased through vaccination, which is also a key component of disease prevention and control. Moreover, new vaccine manufacturing techniques have emerged due to advances in technology, medicine, and basic scientific fields like immunology, molecular biology, microbiology, and biochemistry. The application of newer vaccination theories has been aided by genetic engineering, proteomics, and other cutting-edge technologies, leading to the discovery of new ruminant vaccines and the improvement of current ones. The next generation of vaccinations, which are being examined as potential alternatives to traditional immunizations, include subunit, recombinant, DNA, and vector.

Additionally, there are increasing vaccine launches for animals. For instance, Boehringer Ingelheim India introduced VAXXITEK HVT+IBD, a vaccine for poultry, in May 2021. All varieties of producing hens, including broiler, layer, and breeder chickens, are guaranteed lifelong protection by a novel recombinant vaccine called VAXXITEK HVT+IBD. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global animal biotechnology market

In 2021, North American animal biotechnology accounted for the highest revenue share in the global market. The increasing prevalence of zoonotic diseases, advances in genetic engineering in animals, and increasing initiatives and campaigns to promote animal health in the region are driving the market in the forecast period. For instance, according to Dr. Mark Walton, Chief Technology Officer at AquaBounty Technologies, AquAdvantage Salmon (AAS) presents several opportunities for addressing the impending fish shortage and developing a variety of nutrient-rich foods. According to Dr. Walton, AAS has faster development and improved feed efficiency, so it requires less time in water and feeds to get a kilo of proteins. The scientist added that AAS genetics is crucial to the system's profitability and that the AquAdvantage system is witnessing a significant rise in investment. The scientist asserted that the spread of salmon farming in recirculating aquaculture systems on land in the US and internationally would be significantly aided by AquAdvantage.

Furthermore, the Canadian Agricultural Partnership will start contributing up to $4 million in January 2021 to give farmers better access to veterinary services when and when they need them. To enable a collaborative and coordinated approach to transform technologies in the field of veterinary vaccines, biologicals, and diagnostics, TRPVB is a cooperation initiative between the Department of Biotechnology, India, and TANUVAS-Chennai. Therefore, it has increased the demand for animal biotechnology in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the animal biotechnology market are Boehringer Ingelheim GmbH, Merck & Co.,Inc., Virbac, Elanco, Zoetis, Biogenesis Bago, Idexx Laboratories, Heska Corporation, Indian Immunologicals Ltd. and HESTER BIOSCIENCES LIMITED.

Boehringer Ingelheim GmbH:

Overview:

Boehringer Ingelheim is one of Germany's leading contract manufacturers of biopharmaceuticals based on cell cultures and microorganisms. The company is divided into three business areas: human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Moreover, in the animal health sector, Boehringer Ingelheim is one of the world's leading suppliers of vaccines, therapeutics and preventive products that protect animals from disease and pain. In addition, the company achieved net sales of around 4.3 billion euros in the animal health sector in 2021, corresponding to 21 percent of the total net sales. The company's integrated product portfolio includes more than 200 products for dogs, cats, horses, pigs, cattle and poultry. The parasiticides NEXGARD and FRONTLINE for dogs and cats, HEARTGARD for dogs, and the pig vaccines INGELVAC CIRCOFLEX/ FLEXBOMBO are among the best-known brands. Furthermore, the company has an established global animal health innovation network with 18 R&D sites worldwide. The focus is innovative vaccines and parasiticides to protect livestock and companion animals and therapeutics for treating chronic diseases and other debilitating conditions.

Product Portfolio:

Ingelvac PRRS MLV: Ingelvac PRRS MLV is a modified live PRRS vaccine that is safe in pigs, gilts, and sows at all stages of production in PRRS-positive herds. It offers cross-protection against heterologous challenges; (including the Lelystad virus) and has significantly reduced reproductive disorders and respiratory disease due to the PRRS virus.

  • Trusted and field-proven
  • Cost-effective
  • Unique in its ability to be used in pigs (3 weeks or older), gilts, and sows at ANY stage of production
  • Available in three convenient sizes (10, 50, and 250 doses)

The global animal biotechnology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Recent advances in genetic engineering are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of animal biotechnology products is expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Animal Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 7.1.2. Market Attractiveness Index, By Animal Type Segment
  • 7.2. Livestock*
      • 7.2.1.1. Fish
      • 7.2.1.2. Poultry
      • 7.2.1.3. Swine
      • 7.2.1.4. Cattle
      • 7.2.1.5. Sheep & Goats
      • 7.2.1.6. Others
      • 7.2.1.6.1. Introduction
      • 7.2.1.6.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Companion
      • 7.3.1.1. Canine
      • 7.3.1.2. Feline
      • 7.3.1.3. Equine
      • 7.3.1.4. Aquatic
      • 7.3.1.5. Avian
      • 7.3.1.6. Others

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.1.2. Market Attractiveness Index, By Product Type Segment
  • 8.2. Drugs*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccinations
  • 8.4. Diagnostic Tests
  • 8.5. Genetic & Reproductive Products
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Diagnosis of Animal Diseases*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Treatment of Animal Diseases
  • 9.4. Preventive Care of Animals
  • 9.5. Drug Development
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Veterinary Hospitals & Clinics*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Laboratories
  • 10.4. In-house Testing
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boehringer Ingelheim GmbH*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co.,Inc.
  • 13.3. Virbac
  • 13.4. Elanco
  • 13.5. Zoetis
  • 13.6. Biogenesis Bago
  • 13.7. Idexx Laboratories
  • 13.8. Heska Corporation
  • 13.9. Indian Immunologicals Ltd.
  • 13.10. HESTER BIOSCIENCES LIMITED

LIST NOT EXHAUSTIVE

14. Global Animal Biotechnology Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us